Evidence map›Paper›PMID 40099126›Full record

ArticleRevista de salud publica (Bogota, Colombia)2023

[Association between SARS-COV-2 and chronic diseases in health personnel. A preventive medicine program].

Daniel Y Chavarría-Castro, Estefanía Reyes-Varón, Angélica M Salgado-Cordero, Irene Irisson-Mora, Luis E Morales-Bartolo, Fabiola Álvarez-Montero

Abstract readEnglish Abstract
In one paragraph

Article in Revista de salud publica (Bogota, Colombia), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniel Y Chavarría-CastroDC: MD. Esp. Epidemiología. Unidad de Vigilancia Epidemiológica Hospitalaria, Hospital Juárez de México. Ciudad de México, México. dr.daniel-yair.c@hotmail.com Unidad de Vigilancia Epidemiológica Hospitalaria Hospital Juárez de México Ciudad de México México.
Estefanía Reyes-VarónER: MD. Medicina Preventiva. Instituto Nacional de Enfermedades Respiratorias (INER). Ciudad de México, México. fany-0116@hotmail.com Medicina Preventiva Instituto Nacional de Enfermedades Respiratorias (INER) Ciudad de México México.
Angélica M Salgado-CorderoAS: MD. Medicina Preventiva. Instituto Nacional de Enfermedades Respiratorias (INER). Ciudad de México, México. annsalgadoc@gmail.com Medicina Preventiva Instituto Nacional de Enfermedades Respiratorias (INER) Ciudad de México México.
Irene Irisson-MoraII: MD. Esp. Endocrinología. Medicina Preventiva, Instituto Nacional de Enfermedades Respiratorias (INER). Ciudad de México, México. irene_irisson@hotmail.com Endocrinología. Medicina Preventiva Instituto Nacional de Enfermedades Respiratorias (INER) Ciudad de México México.
Luis E Morales-BartoloLM: MD. Medicina Preventiva, Instituto Nacional de Enfermedades Respiratorias (INER). Ciudad de México, México. Medicina Preventiva Instituto Nacional de Enfermedades Respiratorias (INER) Ciudad de México México.
Fabiola Álvarez-MonteroFA: MD. Esp. Epidemiología. Unidad de Vigilancia Epidemiológica Hospitalaria, Hospital Regional No. 2, Instituto Mexicano del Seguro Social. Ciudad de México, México. resi_alva19@hotmail.com Instituto Mexicano del Seguro Social Epidemiología Unidad de Vigilancia Epidemiológica Hospitalaria Instituto Mexicano del Seguro Social. Ciudad de México Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The SARS-CoV-2 infection has been linked to hypertension, obesity and diabetes as risks of hospitalization and death. Regarding obstructive pulmonary diseases, the scientific literature is diverse; finding variation in the frequency of these and therefore their relationship with COVID-19. The available evidence only details hospitalized patients, with insufficient information referring to health workers, so analyzing the main comorbidities in this group is helpful for the implementation and improvement of preventive programs. The objective of this study was to describe the prevalence and association of comorbidities with SARS-CoV-2 infection in health care workers. Methods: Analytical cross-sectional study, in workers of the main national reference center for respiratory diseases in Mexico, who came to care to rule out SARS-CoV-2 infection through a preventive program; calculation of proportions was performed for the sample size. Summary and association measures were calculated. Results: The prevalence of COVID-19 was 22.9 %. The most frequent comorbidities were: overweight obesity, smoking, hypertension, allergic rhinitis and asthma, with prevalences of 29.0 %, 13.2 %, 8.6 %, 5.5 %, 3.9%, 2.8 % respectively. Overweight, obesity and vaccination against SARS-CoV-2 had Prevalence Ratios of 1.78, 1.72 and 0.43 respectively. Conclusions: Obesity and overweight show association with SARS-CoV-2; vaccination is a protective factor, especially in people with comorbidities.

Indexed as

COVID-19health personnelobesityoverweightpreventive medicineSARS-CoV-2vaccination (source: MeSH, NLM)

Identifiers

PMID40099126
PMCPMC11254135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.